PP Reddit Mentions | ChartExchange

I've been looking at Novo for a few months now, being a user of their newly released drugs and quite impressed with the results; here's an excerpt of my updated analysis (done by my friend Claude but good nonetheless - Opus 5 tends to be quite thorough):

The thesis, in one sentence: Novo Nordisk has ceased to be a growth story and has become a large, highly profitable pharmaceutical business with an expiring franchise — and at $39.72, the price does not yet fully reflect this transition, because the market found out only today, September 21, 2026, from the company itself, that the 2026–2030 growth rate will be "in line with industry peers."
The day I am writing this report is no coincidence. At the Capital Markets Day in London, held just today, management put on paper three ambitions for 2030: revenue growth in line with industry peers, a "broadly stable" adjusted operating margin, and an attractive dividend per share, plus over five launches with multi-blockbuster potential and over 150 billion DKK in risk-adjusted pipeline sales by 2035. The stock dropped 7% intraday and closed around $39.7, down from $43.24 on Friday. The reason for the drop is not that the targets are bad in themselves, but that they officially confirm the end of the 20%+ annual growth regime that drove the stock to $131.81 in June 2024. From that peak, NVO is down −70%.
**What I found in the numbers, beyond the narrative. Three things completely change what "cheap" looks like for Novo:**
* **The trailing twelve months (TTM) profit is inflated by a 26.8 billion DKK accounting artifact.** In Q1 2026, the company fully reversed the $4.2 billion provision for the 340B program, recognizing it as revenue with zero cash impact (*caq22026.htm*, Appendix 3, note 1). This brought reported Q1 revenues to +32% CER and operating profit to +65% CER, when adjusted sales were actually down 4% CER. The 9.86× P/E from the data pack and the 35.3% net margin from the tracker are calculated on this basis. On an adjusted basis, the TTM P/E is 11.2× and the P/E on my 2026 estimate is 12.3×. Cheap — but not what it seems.
* **Free cash flow is compressed by a capex supercycle that hasn't ended.** PP&E capex grew from 6.3 billion DKK in 2021 to 60.1 billion in 2025 (\~55 billion guidance for 2026), compared to depreciation of only \~15–16 billion. Simple FCF for 2025 was 28.99 billion DKK, and TTM FCFE was 45.03 billion — below a 4.2% yield on market capitalization. The company promises that investment "will decrease in the coming years," but does not say by how much or when.
* **The gross margin is eroding visibly, not marginally.** 84.7% in 2024 →right arrow → 81.0% in 2025 →right arrow → 79.3% adjusted in H1 2026 →right arrow → 78.2% in Q2 2026. The stated cause: lower realized prices, plus one-off costs of \~3 billion DKK from resizing manufacturing capacity contracts. And the list price cuts agreed upon with the US administration only take effect on January 1, 2027: Wegovy −50%, Ozempic −35%, down to $675 per month.
**Estimated value.** I start from a normalized owner earnings base of 58,000 million DKK (details and bridge in the valuation chapter), grow it at 4% in year 1 declining toward a 1.5% terminal rate, discount at 9%, and subtract net debt of 95.64 billion DKK. Five triangulated models yield a range from −59.4% (bear DCF) to +14.8% (bull DCF), with a median of −17.3%. A Monte Carlo simulation across 20,000 runs using the same assumptions yields a median intrinsic value of **$27.38** compared to **$39.72**, showing an undervaluation probability of 15.0% and a probability of a margin of safety above 30% of just 3.6%.

.dark-mode .sPqN20{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .sPqN20{ color: #333333; background-color: white; border: 2px solid #333333; }PPThe Meet Kevin Pricing Power ETFstock NYSE

PP
The Meet Kevin Pricing Power ETF
stock NYSE